Romain Kessler
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Romain Kessler has a total of 646 co-authors. Here are the top co-authors by number of shared publications:
Ari Chaouat
9 shared publicationsEmmanuel Weitzenblum
Department of Pulmonology, Nouvel Hôpital Civil, Strasbourg
9 shared publications- Benjamin Renaud-Picard
Department of Pneumology, Strasbourg Lung Transplant Program, Strasbourg University Hospital, Strasbourg, France
7 shared publications - Sandrine Hirschi
Pneumology Department, Lung Transplant Program, NHC, Strasbourg University Hospital, Strasbourg, France
6 shared publications Matthieu Canuet
5 shared publicationsTristan Dégot
Division of Respiratology and Strasbourg Lung Transplant Program, Nouvel Hôpital Civil, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
5 shared publications
Latest Publications
- Open Access
- 22 October 2026
- Published by European Respiratory Society (ERS) in ERJ Open Research
Longitudinal Trajectories and Incidence of Obesity-Hypoventilation Syndrome Over Three Years in Obese Adults (The Cohypob Study)
Background: Obesity hypoventilation syndrome (OHS) is defined by daytime hypercapnia in obese individuals and is often considered the consequence of progressive nocturnal hypoventilation. However, the natural history of obesity-related nocturnal hypoventilation (ONH) and its progression toward OHS remain poorly understood. Methods: COHYPOB is a prospective multicentre cohort study including obese adults without daytime hypercapnia or obstructive sleep apnoea requiring CPAP at baseline. Participants underwent comprehensive clinical, respiratory, metabolic and sleep assessments at inclusion and during a 3-year follow-up. ONH was defined using elevated morning serum bicarbonate (≥27 mmol·L⁻ 1 ) in the absence of daytime hypercapnia, according to current ERS Task Force recommendations. The primary outcome was the occurrence of OHS, defined by daytime PaCO₂ ≥45 mmHg. Results: A total of 162 participants were included (74% women, mean age 48±14 years, mean BMI 37.3±4.9 kg·m⁻ 2 ). Among the 144 participants with available baseline serum bicarbonate measurements, 67 (46.5%) met the criterion for bicarbonate-defined ONH. Compared with those without ONH, affected individuals were older and showed mild alterations in daytime gas exchange and nocturnal oxygenation despite similar body mass index. Over the 3-year follow-up, body weight remained stable, whereas bicarbonate-defined ONH demonstrated marked temporal variability. Five participants developed OHS, corresponding to an incidence of 5.4% among those completing follow-up. Conclusions: In this prospective cohort of obese adults without daytime hypercapnia and without OSA requiring CPAP, bicarbonate-defined ONH was common and showed substantial temporal variability over three years, whereas incident OHS remained uncommon. These observations suggest that the evolution towards OHS may be more heterogeneous than traditionally proposed. Because ONH was defined using morning serum bicarbonate, longitudinal studies incorporating direct nocturnal CO₂ monitoring are required.
- 22 October 2026
- Published by European Respiratory Society (ERS) in ERJ Open Research
Open AccessLongitudinal Trajectories and Incidence of Obesity-Hypoventilation Syndrome Over Three Years in Obese Adults (The Cohypob Study)
Background: Obesity hypoventilation syndrome (OHS) is defined by daytime hypercapnia in obese individuals and is often considered the consequence of progressive nocturnal hypoventilation. However, the natural history of obesity-related nocturnal hypoventilation (ONH) and its progression toward OHS remain poorly understood. Methods: COHYPOB is a prospective multicentre cohort study including obese adults without daytime hypercapnia or obstructive sleep apnoea requiring CPAP at baseline. Participants underwent comprehensive clinical, respiratory, metabolic and sleep assessments at inclusion and during a 3-year follow-up. ONH was defined using elevated morning serum bicarbonate (≥27 mmol·L⁻ 1 ) in the absence of daytime hypercapnia, according to current ERS Task Force recommendations. The primary outcome was the occurrence of OHS, defined by daytime PaCO₂ ≥45 mmHg. Results: A total of 162 participants were included (74% women, mean age 48±14 years, mean BMI 37.3±4.9 kg·m⁻ 2 ). Among the 144 participants with available baseline serum bicarbonate measurements, 67 (46.5%) met the criterion for bicarbonate-defined ONH. Compared with those without ONH, affected individuals were older and showed mild alterations in daytime gas exchange and nocturnal oxygenation despite similar body mass index. Over the 3-year follow-up, body weight remained stable, whereas bicarbonate-defined ONH demonstrated marked temporal variability. Five participants developed OHS, corresponding to an incidence of 5.4% among those completing follow-up. Conclusions: In this prospective cohort of obese adults without daytime hypercapnia and without OSA requiring CPAP, bicarbonate-defined ONH was common and showed substantial temporal variability over three years, whereas incident OHS remained uncommon. These observations suggest that the evolution towards OHS may be more heterogeneous than traditionally proposed. Because ONH was defined using morning serum bicarbonate, longitudinal studies incorporating direct nocturnal CO₂ monitoring are required.
- Open Access
- 21 August 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 45 (1) , 37-46
Diagnostic significance of intragraft donor–specific anti-HLA antibodies in pulmonary antibody–mediated rejection
- 21 August 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 45 (1) , 37-46
Open AccessDiagnostic significance of intragraft donor–specific anti-HLA antibodies in pulmonary antibody–mediated rejection
- Open Access
- 7 February 2023
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 42 (7) , 908-916
A randomized controlled trial of presatovir for respiratory syncytial virus after lung transplant
- 7 February 2023
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 42 (7) , 908-916
Open AccessA randomized controlled trial of presatovir for respiratory syncytial virus after lung transplant
- 16 July 2022
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 41 (10) , 1429-1439
Torque teno virus DNA load as a predictive marker of antibody response to a three-dose regimen of COVID-19 mRNA-based vaccine in lung transplant recipients
- 16 July 2022
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 41 (10) , 1429-1439
Torque teno virus DNA load as a predictive marker of antibody response to a three-dose regimen of COVID-19 mRNA-based vaccine in lung transplant recipients
- Open Access
- 26 April 2022
- Published by Elsevier in American Journal of Transplantation
- Vol. 22 (7) , 1861-1872
Feasibility and efficacy of combined pancreatic islet-lung transplantation in cystic fibrosis-related diabetes–PIM study: A multicenter phase 1–2 trial
- 26 April 2022
- Published by Elsevier in American Journal of Transplantation
- Vol. 22 (7) , 1861-1872
Open AccessFeasibility and efficacy of combined pancreatic islet-lung transplantation in cystic fibrosis-related diabetes–PIM study: A multicenter phase 1–2 trial
- Open Access
- 7 May 2021
- Published by S. Karger AG in Respiration
- Vol. 100 (8) , 804-810
Endobronchial Coil System versus Standard-of-Care Medical Management in the Treatment of Subjects with Severe Emphysema
Background: Bronchoscopic lung volume reduction using endobronchial coils is a new treatment for patients with severe emphysema. To date, the benefits have been modest and have been suggested to be much larger in patients with severe hyperinflation and nonmulti-comorbidity. Objective: We aimed to evaluate the efficacy and safety of endobronchial coil treatment in a randomized multicenter clinical trial using optimized patient selection. Method: Patients with severe emphysema on HRCT scan with severe hyperinflation (residual volume [RV] ≥200% predicted and RV/total lung capacity [TLC] >55%) were randomized to coil treatment or control. Primary outcome measures were differences in the forced expiratory volume in 1 s (FEV1) and St George’s Respiratory Questionnaire (SGRQ) total score at 6 months. Results: Due to premature study termination, a total of 120 patients (age 63 ± 7 years, FEV1 29 ± 7% predicted, RV 251 ± 41% predicted, RV/TLC 67 ± 6%, and SGRQ 58 ± 13 points), instead of 210 patients, were randomized. At study termination, 91 patients (57 coil and 34 control) had 6-month results available. Analyses showed significantly greater improvements in favor of the coil group. The increase in FEV1 was greater in the coil group than that in the control group by + 10.3 [+4.7 to +16.0] % and in SGRQ by −10.6 [−15.9 to −5.4] points. At study termination, there were 5 (6.8%) deaths in the coil cohort reported. Conclusion: Despite early study termination, coil treatment compared to control results in a significant improvement in the lung function and quality of life benefits for up to 6 months in patients with emphysema and severe hyperinflation. These improvements were of clinical importance but were associated with a higher likelihood of serious adverse events.
- 7 May 2021
- Published by S. Karger AG in Respiration
- Vol. 100 (8) , 804-810
Open AccessEndobronchial Coil System versus Standard-of-Care Medical Management in the Treatment of Subjects with Severe Emphysema
Background: Bronchoscopic lung volume reduction using endobronchial coils is a new treatment for patients with severe emphysema. To date, the benefits have been modest and have been suggested to be much larger in patients with severe hyperinflation and nonmulti-comorbidity. Objective: We aimed to evaluate the efficacy and safety of endobronchial coil treatment in a randomized multicenter clinical trial using optimized patient selection. Method: Patients with severe emphysema on HRCT scan with severe hyperinflation (residual volume [RV] ≥200% predicted and RV/total lung capacity [TLC] >55%) were randomized to coil treatment or control. Primary outcome measures were differences in the forced expiratory volume in 1 s (FEV1) and St George’s Respiratory Questionnaire (SGRQ) total score at 6 months. Results: Due to premature study termination, a total of 120 patients (age 63 ± 7 years, FEV1 29 ± 7% predicted, RV 251 ± 41% predicted, RV/TLC 67 ± 6%, and SGRQ 58 ± 13 points), instead of 210 patients, were randomized. At study termination, 91 patients (57 coil and 34 control) had 6-month results available. Analyses showed significantly greater improvements in favor of the coil group. The increase in FEV1 was greater in the coil group than that in the control group by + 10.3 [+4.7 to +16.0] % and in SGRQ by −10.6 [−15.9 to −5.4] points. At study termination, there were 5 (6.8%) deaths in the coil cohort reported. Conclusion: Despite early study termination, coil treatment compared to control results in a significant improvement in the lung function and quality of life benefits for up to 6 months in patients with emphysema and severe hyperinflation. These improvements were of clinical importance but were associated with a higher likelihood of serious adverse events.
- Open Access
miRNAs Potentially Involved in Post Lung Transplant-Obliterative Bronchiolitis: The Role of miR-21-5p
Epigenetic changes, including miRNAs deregulation, have been suggested to play a significant role in development of obliterative bronchiolitis (OB) in transplanted lungs. Many studies have tried to identify ideal candidate miRNAs and the downstream pathways implicated in the bronchiolar fibro-obliterative process. Several candidate miRNAs, previously indicated as possibly being associated with OB, were analyzed by combining the quantitative real time-polymerase chain reaction (qRT-PCR) and in situ hybridization (ISH) of lung tissues of OB affected patients. Disease and OB-lesion-specific expression of miR-21-5p was confirmed and by computational analysis we were able to identify the network of genes most probably associated miR-21-5p in the context of OB fibrogenesis. Among all potentially associated genes, STAT3 had a very high probability score. Immunohistochemistry showed that STAT3/miR-21-5p were co-over expressed in OB lesions, thus, suggesting miR-21-5p could regulate STAT3 expression. However, miR-21-5p inhibition in cultures of bronchiolitis obliterans syndrome (BOS) derived myofibroblasts did not significantly affect STAT3 mRNA and protein expression levels. This study demonstrates the specificity of miR-21-5p over-expression in OB lesions and contributes to existing knowledge on the miR-21-5p downstream pathway. Activation of STAT3 is associated with miR-21-5p upregulation, however, STAT-3 network activation is most likely complex and miR-21-5p is not the sole regulator of STAT3.
Open AccessmiRNAs Potentially Involved in Post Lung Transplant-Obliterative Bronchiolitis: The Role of miR-21-5p
Epigenetic changes, including miRNAs deregulation, have been suggested to play a significant role in development of obliterative bronchiolitis (OB) in transplanted lungs. Many studies have tried to identify ideal candidate miRNAs and the downstream pathways implicated in the bronchiolar fibro-obliterative process. Several candidate miRNAs, previously indicated as possibly being associated with OB, were analyzed by combining the quantitative real time-polymerase chain reaction (qRT-PCR) and in situ hybridization (ISH) of lung tissues of OB affected patients. Disease and OB-lesion-specific expression of miR-21-5p was confirmed and by computational analysis we were able to identify the network of genes most probably associated miR-21-5p in the context of OB fibrogenesis. Among all potentially associated genes, STAT3 had a very high probability score. Immunohistochemistry showed that STAT3/miR-21-5p were co-over expressed in OB lesions, thus, suggesting miR-21-5p could regulate STAT3 expression. However, miR-21-5p inhibition in cultures of bronchiolitis obliterans syndrome (BOS) derived myofibroblasts did not significantly affect STAT3 mRNA and protein expression levels. This study demonstrates the specificity of miR-21-5p over-expression in OB lesions and contributes to existing knowledge on the miR-21-5p downstream pathway. Activation of STAT3 is associated with miR-21-5p upregulation, however, STAT-3 network activation is most likely complex and miR-21-5p is not the sole regulator of STAT3.
- Open Access
- 1 November 2020
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 15, 2807-2816
Two-Year Outcomes for the Double-Blind, Randomized, Sham-Controlled Study of Targeted Lung Denervation in Patients with Moderate to Severe COPD: AIRFLOW-2
Purpose: COPD exacerbations are associated with worsening clinical outcomes and increased healthcare costs, despite use of optimal medical therapy. A novel bronchoscopic therapy, targeted lung denervation (TLD), which disrupts parasympathetic pulmonary innervation of the lung, has been developed to reduce clinical consequences of cholinergic hyperactivity and its impact on COPD exacerbations. The AIRFLOW-2 study assessed the durability of safety and efficacy of TLD additive to optimal drug therapy compared to sham bronchoscopy and optimal drug therapy alone in subjects with moderate-to-severe, symptomatic COPD two years post randomization. Patients and Methods: TLD was performed in COPD patients (FEV1 30– 60% predicted, CAT≥ 10 or mMRC≥ 2) in a 1:1 randomized, sham-controlled, double-blinded multicenter study (AIRFLOW-2) using a novel lung denervation system (Nuvaira, Inc., USA). Subjects remained blinded until their 12.5-month follow-up visit when control subjects were offered the opportunity to undergo TLD. A time-to-first-event analysis on moderate and severe and severe exacerbations of COPD was performed. Results: Eighty-two subjects (FEV1 41.6± 7.4% predicted, 50.0% male, age 63.7± 6.8 yrs, 24% with prior year respiratory hospitalization) were randomized. Time-to-first severe COPD exacerbation was significantly lengthened in the TLD arm (p=0.04, HR=0.38) at 2 years post-TLD therapy and trended towards similar attenuation for moderate and severe COPD exacerbations (p=0.18, HR=0.71). No significant changes in lung function or SGRQ-C were found 2 years post randomization between groups. Conclusion: In a randomized trial, TLD demonstrated a durable effect of significantly lower risk of severe AECOPD over 2 years. Further, lung function and quality of life remained stable following TLD. Clinical Trial Registration: NCT02058459.
- 1 November 2020
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 15, 2807-2816
Open AccessTwo-Year Outcomes for the Double-Blind, Randomized, Sham-Controlled Study of Targeted Lung Denervation in Patients with Moderate to Severe COPD: AIRFLOW-2
Purpose: COPD exacerbations are associated with worsening clinical outcomes and increased healthcare costs, despite use of optimal medical therapy. A novel bronchoscopic therapy, targeted lung denervation (TLD), which disrupts parasympathetic pulmonary innervation of the lung, has been developed to reduce clinical consequences of cholinergic hyperactivity and its impact on COPD exacerbations. The AIRFLOW-2 study assessed the durability of safety and efficacy of TLD additive to optimal drug therapy compared to sham bronchoscopy and optimal drug therapy alone in subjects with moderate-to-severe, symptomatic COPD two years post randomization. Patients and Methods: TLD was performed in COPD patients (FEV1 30– 60% predicted, CAT≥ 10 or mMRC≥ 2) in a 1:1 randomized, sham-controlled, double-blinded multicenter study (AIRFLOW-2) using a novel lung denervation system (Nuvaira, Inc., USA). Subjects remained blinded until their 12.5-month follow-up visit when control subjects were offered the opportunity to undergo TLD. A time-to-first-event analysis on moderate and severe and severe exacerbations of COPD was performed. Results: Eighty-two subjects (FEV1 41.6± 7.4% predicted, 50.0% male, age 63.7± 6.8 yrs, 24% with prior year respiratory hospitalization) were randomized. Time-to-first severe COPD exacerbation was significantly lengthened in the TLD arm (p=0.04, HR=0.38) at 2 years post-TLD therapy and trended towards similar attenuation for moderate and severe COPD exacerbations (p=0.18, HR=0.71). No significant changes in lung function or SGRQ-C were found 2 years post randomization between groups. Conclusion: In a randomized trial, TLD demonstrated a durable effect of significantly lower risk of severe AECOPD over 2 years. Further, lung function and quality of life remained stable following TLD. Clinical Trial Registration: NCT02058459.